The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application XEOMIN® (incobotulinumtoxinA).
The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Merz Therapeutics’ XEOMIN® (incobotulinumtoxinA) to treat patients aged 2 years and older who have upper limb spasticity, not including spasticity caused by cerebral palsy.1 It is the first approved pediatric indication for the drug. The FDA will also be deciding on an approval for incobotulinumtoxinA to treat pediatric cases of sialorrhea near the end of the year.
The approval was based on a Phase 3 study of 350 patients aged 2 to 17 years that looked at the safety and efficacy of incobotulinumtoxinA. Primary efficacy endpoints were changed from baseline on the 5-point Ashworth Scene and a 7-point Investigator’s Global Impression of Change Scale at the fourth week of treatment. The study illustrated sustained improvement in muscle tone in all upper limb muscle groups including flexed elbow, flexed wrist, forearm pronators, clenched fist, and thumb-in-palm. It also confirmed it was safe for bilateral treatment with up to 400 units per treatment. In clinical trials with 900 pediatric spasticity patients, no patient developed a clinical resistance to incobotulinumtoxinA. There was no evidence that higher dosing led to increased incidence of adverse reactions.
In the press release from Merz Therapeutics, Kevin O’Brien, President of North America said, “With the need for prolonged treatment, it is critical for children and adolescents with upper limb spasticity to have a long-term flexible treatment option to help manage their condition over time. At Merz Therapeutics, we designed our clinical trial program with 12 upper limb muscles to offer the most flexibility of any botulinum toxin, in order to offer patients, caregivers and doctors a safe and effective treatment option that meets the needs of pediatric patients.”
Reference
1. FDA approves first pediatric indication for xeomin® (incobotulinumtoxina) for the treatment of upper limb spasticity, excluding spasticity caused by cerebral palsy | Merz USA. Merz USA. Published August 19, 2020. Accessed August 19, 2020. https://www.merzusa.com/news/fda-approves-first-pediatric-indication-for-xeomin/.
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.